Direct compression with Tianma Powder veterinary-grade API requires that the powder be matched to rotary press feed frame behavior rather than to laboratory hand-fill conditions. If the Dv90 measured by laser diffraction per USP <429> exceeds 250 µm, the lot is passed through a conical mill fitted with a 0.020 in. round-hole screen at 1,200 rpm; this controls oversize that otherwise raises weight variation at press speeds above 40 rpm. Flow function coefficient is measured on a Schulze ring shear tester per ASTM D6773-22; values below 4.0 indicate that gravity-fed die filling is not reliable, and the formula is switched to roller compaction or wet granulation. For direct compression, a twin-shell V-blender with intensifier bar is operated at 25 rpm for 10 min to prepare a 1:10 pre-blend, followed by a 1:100 main blend. Magnesium stearate is screened through a 60 mesh sieve and added at 0.25% w/w to 1.0% w/w; over-lubrication above 2.0% w/w depresses tablet tensile strength below the 1.7 MPa threshold needed for chewable veterinary tablets tested by diametral compression. A rotary tablet press with forced feed is operated at 20–35 kN compaction force and 30–50 rpm; fill weight is checked every 15 min using 10 tablets, and final dose uniformity is assessed by USP <905> with an acceptance value not more than 15.0. Disintegration is run by USP <701> in 37 ± 2 °C water, with a limit of 15 min for immediate-release veterinary tablets. Dissolution release uses USP <711> Apparatus 2 at 50 rpm, with Q = 80% at 30 min unless a veterinary monograph specifies otherwise.

What Limits Sterile Filtration Throughput in Injectable Solutions?

Sterile injectable manufacture using the API powder begins with solubility mapping in compendial buffers. If the lot dissolves to at least 20 mg/mL in a pH 4.0–6.5 citrate or phosphate buffer at 20–25 °C, the solution can be processed through a 0.45 µm prefilter and a final 0.22 µm membrane. Throughput limitations are governed by filter-loading capacity, solution viscosity, and the particle load remaining after reconstitution. A 10-inch cartridge train with 0.45 µm prefiltration and 0.22 µm final filtration is operated with differential pressure below 2.0 bar; a pressure above 1.5 bar during the first 10 min signals the need for clarification by centrifugation or bag filtration. The final filter integrity is tested before and after filling using the filter manufacturer's validated bubble point specification, and bacterial retention is supported by ASTM F838-20. If the API solution is thermostable, terminal sterilization at 121 °C for 15 min with F0 ≥ 8.0 is preferred; where thermolability is suspected, stability is assessed per VICH GL3, and published data for this specific configuration is limited. In thermolabile cases, the process defaults to aseptic filtration through a sterilizing-grade membrane into depyrogenated vials in a Class A isolator with Class B background per EU GMP Annex 1. If solubility is below 10 mg/mL at target pH, a cosolvent or pH adjustment is required; below 1 mg/mL, solution presentation is not practical and suspension or lyophilization should be considered.

Fill volume tolerance for 10 mL vials is set at ±1.0%, and the filling line uses a Bausch+Ströbel VarioSys aseptic filling machine equipped with peristaltic pumps; contact tubing is replaced after 8 h to limit leachable accumulation. Post-fill inspection distinguishes visible particulates per USP <790>, while subvisible particulate limits follow USP <788>: not more than 6,000 particles per container ≥10 µm and not more than 600 particles per container ≥25 µm for small-volume injections. Endotoxin load is calculated from K/M per USP <85>; with K = 5 EU/kg and a maximum veterinary dose of 10 mg/kg, the limit is 0.5 EU/mg. Media fill acceptance follows EU GMP Annex 1, and environmental monitoring is continued through the fill; any positive unit in a run of 5,000 triggers a process review. If oxidative degradation is identified by forced degradation per VICH GL3, the formulation is protected by nitrogen purging to dissolved oxygen below 0.5 ppm and sodium metabisulfite at 0.1% w/v. Amine-based buffers are avoided if the active contains ester moieties because aminolysis can lower assay below 95.0%; this incompatibility is documented by pH-rate studies.

Unlike compression-based tablet lines, powder-in-capsule filling shifts the critical control point from compaction mechanics to tamping-pin densification and shell moisture exchange. The API powder is preblended with microcrystalline cellulose or pregelatinized starch through a 1:10 geometric dilution in a 250 L bin blender at 8 rpm for 15 min. For size 0 hard gelatin capsules, a Bosch GKF 2600 tamping-pin capsule filler is configured with tamping force at station 3 limited to 200 N to avoid cake formation; fill weight is checked every 30 min on 20 capsules, and variation is maintained within ±5.0%. When dynamic vapor sorption shows moisture uptake above 2.0% w/w at 50% RH, the filling suite is held at ≤30% RH; for HPMC shells, the room is kept at 35–45% RH because conditions below 30% RH increase shell brittleness and ejection defects. Capsule contents are tested for dissolution by USP <711> Apparatus 1 at 100 rpm, with Q = 80% at 30 min. Because no compression is applied, tableting-induced polymorphic transformation is avoided, but hygroscopic fill blends may still require a silica gel desiccant at 1 g per 10 capsules in HDPE packaging; moisture pick-up is monitored over 12 months at 25 °C/60% RH per VICH GL3.

Sachet powder segregation and the geometric dilution threshold

For oral powder sachets, segregation control is the dominant release risk. When the label claim is below 100 mg per sachet, a 1:10 pre-blend and a 1:100 main blend are screened through a 30 mesh stainless steel sieve before mixing in a 500 L bin blender at 8 rpm for 20 min. Segregation potential is tested by sampling the top, middle, and bottom of the blender after 5 min of vibration on a sieve shaker; an assay difference above 5.0% relative to the mean indicates the need for finer API particles or 0.5% w/w colloidal silicon dioxide. Sachet filling is carried out on a vertical form-fill-seal line with an auger filler; for a 2 g target fill weight, fill weight variation is maintained within ±7.5%, and seal integrity is tested at 200–300 mbar vacuum. Foil laminate moisture barrier is selected by water vapor transmission rate per ASTM F1249-20; a laminate with 0.06 g/m²/day at 38 °C/90% RH is used for moisture-sensitive formulas. Finished sachet dose uniformity is assessed by USP <905> with an acceptance value not more than 15.0; the auger fill speed is limited to 40 strokes/min if the powder has a Carr Index above 25 as measured by USP <1174>.

Producing free-flowing oral granules from the API powder begins with fluid-bed top-spray granulation in a Glatt GPCG 3 unit equipped with a 1.2 mm twin-fluid nozzle. The binder phase is prepared by dissolving hydroxypropyl methylcellulose E5 in purified water at 60 °C, cooling to 25 °C, and applying as a 3.0% w/w solution at a spray rate of 12–18 g/min. Inlet air temperature is set to 65 °C; outlet air temperature is maintained between 35 °C and 40 °C; atomization air pressure is 1.5 bar. Granulation endpoint is reached when the Dv50 of the granulate reaches 180–250 µm and loss on drying by USP <731> is 1.0–2.0% w/w. Over-wetting beyond 3.0% w/w residual moisture produces agglomerates that require a 1.0 mm screen and reduces granule flow. After drying, granules are passed through a 12 mesh sieve and retained on a 60 mesh sieve; the 12–60 mesh fraction is filled into sachets or high-density polyethylene bottles. Tap density is controlled between 0.45 g/mL and 0.65 g/mL by adjusting binder viscosity; granules below 0.40 g/mL are rejected because they raise dust and sachet fill variability. Dissolution of immediate-release oral granules is tested by USP <711> Apparatus 2 at 50 rpm, with 80% release at 30 min. For enteric-coated granules, a subcoat of 2.0% w/w hydroxypropyl methylcellulose is followed by a methacrylic acid copolymer dispersion; acid-stage release is not more than 10% after 2 h in 0.1 N HCl, and buffer-stage release is not less than 80% at 45 min in pH 6.8 phosphate buffer. Binder solution is filtered through a 150 µm mesh before spraying to reduce nozzle blockage and batch-to-batch spray rate drift.

When the premix is applied to pelleted feed instead of meal feed

When the premix is applied to pelleted feed instead of meal feed, the API powder must be stabilized in a carrier that withstands post-pelleting coating or surface application without segregation. The premix is manufactured as a Type A medicated article under 21 CFR 226; downstream dilution to Type B or Type C medicated feed falls under 21 CFR 225. A 0.5% w/w active premix is prepared by mixing the API powder with ground limestone or rice hulls in a double-ribbon blender at 20 rpm for 15 min; carrier particle size is matched to the feed pellet diameter to reduce transport segregation. If the premix is applied after pelleting, soybean oil at 1.0% w/w to 2.0% w/w is sprayed onto heated pellets at 45 °C, and the premix is adhered in a rotary coater. For fixed exit mixers, 10 incremental samples are taken per ton from the discharge stream; the assay coefficient of variation must be below 5.0% for medicated feed per FDA-CVM sampling guidance. If the API is heat-sensitive, the premix is not added before pelleting because pellet die temperatures above 70 °C can reduce assay below 95.0%; instead, a vacuum coater at 150 mbar for 8 min is used to achieve a surface distribution variation below 8.0% CV. Finished medicated feed is assayed by HPLC with method validation per VICH GL1 and stability under 25 °C/60% RH for 12 months per VICH GL3. If an iron oxide tracer is required, it is added at 0.1% w/w and the tracer CV below 5.0% is used as a surrogate for blend homogeneity. Published data for this specific API in pelleted feed is limited; therefore, process qualification requires three consecutive production-scale batches with assay RSD below 5.0% before release.

Oral solution manufacturing requires pH adjustment before packaging leachables are evaluated

Oral solution formulas require pH adjustment within a range where the API remains in solution for the entire shelf life. A titration curve is prepared in 0.05 M buffer systems from pH 2.0 to 8.0; if solubility drops below 10 mg/mL at a given pH, that pH region is excluded unless a cosolvent is justified by a stability study. Typical solvent systems use propylene glycol 10.0% v/v to 30.0% v/v or glycerin 5.0% v/v to 15.0% v/v, but feline products avoid propylene glycol because repeated doses above 1.0 g/kg/day have been associated with Heinz body formation. The solution is filled into amber polyethylene terephthalate bottles with child-resistant closures, and headspace oxygen is purged with nitrogen to below 2.0% v/v if forced degradation shows oxidation at 40 °C/75% RH for 6 months per VICH GL3. Preservative systems are selected by antimicrobial effectiveness testing per USP <51>; methylparaben at 0.1% w/v and propylparaben at 0.02% w/v are common choices, but sorbitol may reduce free paraben concentration and require adjustment. pH is checked after batch makeup and adjusted within ±0.1 unit of the registered specification using 1 N hydrochloric acid or sodium hydroxide; pH is measured per USP <791>. Packaging leachables are monitored by storing filled solutions at 40 °C/75% RH for 6 months and testing common extractables by GC-MS or LC-MS per USP <1664>. The oral solution is dosed with calibrated oral syringes or pump dispensers; delivered dose tolerance is ±5.0% for doses above 1 mL and ±10.0% for doses below 1 mL. After final clarification through a 10 µm filter, the solution is filled on a peristaltic pump line at 20–40 bottles/min; extractable polymer tubing is replaced after 8 h of contact to limit leachable accumulation.